HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IFF Q2

This article was originally published in The Rose Sheet

Executive Summary

Fine fragrance sales rose 9% for the second quarter, contributing to a net sales increase of 2.9% to $530.5 mil., International Flavors & Fragrances announces July 26. The performance of fine fragrances was attributed to new product introductions and strong sales of the North American and Latin American divisions, which grew 18% and 17%, respectively. "The fine fragrance team is executing its strategy of building customer brands around the world very well," IFF says. Net fragrance sales advanced 3% with a 1% increase in functional fragrance and a 3% decrease in fragrance ingredient sales, company notes. Net income rose 7.8% to $61.2 mil...

You may also be interested in...



Expanded Lung Cancer Claim For Lilly’s Cyramza Faces US FDA Scrutiny

Oncologic Drugs Advisory Committee will consider whether a statistically significant benefit on progression-free survival, but no survival advantage, is enough to secure a first-line lung cancer indication for ramucirumab.

Hunt On For New Chair Of UK Regulator

Whoever takes over as chair of the Medicines and Healthcare products Regulatory Agency will play a key role in its plans to deliver a program of “ambitious business change.”

Perrigo Rolls Out US ProAir Rival

Perrigo has received US FDA approval for a generic version of Teva’s ProAir albuterol inhaler. The firm is immediately launching a “limited quantity” but is also ramping up production with partner Catalent to meet future demand.

UsernamePublicRestriction

Register

RS014104

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel